Do analysts recommend CGC or CPIX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Canopy Growth 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to CGC or CPIX?

In the previous week, Canopy Growth had 3 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 5 mentions for Canopy Growth and 2 mentions for Cumberland Pharmaceuticals. Canopy Growth's average media sentiment score of 0.91 beat Cumberland Pharmaceuticals' score of 0.55 indicating that Canopy Growth is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Canopy Growth 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cumberland Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer CPIX or AVIR?

Atea Pharmaceuticals has a consensus target price of $7.00, suggesting a potential upside of 28.91%. Given Atea Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Atea Pharmaceuticals is more favorable than Cumberland Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Atea Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Does the media prefer CPIX or AVIR?

In the previous week, Cumberland Pharmaceuticals had 1 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 2 mentions for Cumberland Pharmaceuticals and 1 mentions for Atea Pharmaceuticals. Cumberland Pharmaceuticals' average media sentiment score of 0.55 beat Atea Pharmaceuticals' score of 0.00 indicating that Cumberland Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cumberland Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atea Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate CPIX or FENC?

Adherex Technologies has a consensus price target of $17.00, indicating a potential upside of 50.58%. Given Adherex Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Adherex Technologies is more favorable than Cumberland Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Adherex Technologies 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Do analysts rate CPIX or ENTA?

Enanta Pharmaceuticals has a consensus target price of $19.50, indicating a potential upside of 44.77%. Given Enanta Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Enanta Pharmaceuticals is more favorable than Cumberland Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Enanta Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71

Do analysts prefer CPIX or PALI?

Palisade Bio has a consensus price target of $9.00, indicating a potential upside of 328.57%. Given Palisade Bio's stronger consensus rating and higher probable upside, analysts clearly believe Palisade Bio is more favorable than Cumberland Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Palisade Bio 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.00

Does the media favor CPIX or PALI?

In the previous week, Palisade Bio had 9 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 11 mentions for Palisade Bio and 2 mentions for Cumberland Pharmaceuticals. Cumberland Pharmaceuticals' average media sentiment score of 0.55 beat Palisade Bio's score of -0.21 indicating that Cumberland Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cumberland Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Palisade Bio 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Cumberland Pharmaceuticals (CPIX) Competitors

$7.65 +0.15 (+2.00%)

As of 08/21/2026 04:00 PM Eastern

Compare

CPIX vs. CGC, AVIR, FENC, ENTA, and PALI

Should you buy Cumberland Pharmaceuticals stock or one of its competitors? Cumberland Pharmaceuticals's main competitors and comparable companies include Canopy Growth (CGC), Atea Pharmaceuticals (AVIR), Adherex Technologies (FENC), Enanta Pharmaceuticals (ENTA), and Palisade Bio (PALI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cumberland Pharmaceuticals compare to Canopy Growth?

Canopy Growth (NASDAQ:CGC) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.

In the previous week, Canopy Growth had 3 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 5 mentions for Canopy Growth and 2 mentions for Cumberland Pharmaceuticals. Canopy Growth's average media sentiment score of 0.91 beat Cumberland Pharmaceuticals' score of 0.55 indicating that Canopy Growth is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Canopy Growth	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cumberland Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cumberland Pharmaceuticals has lower revenue, but higher earnings than Canopy Growth. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Canopy Growth	$251.01M	1.88	-$190.29M	-$0.45	N/A
Cumberland Pharmaceuticals	$44.52M	2.57	-$2.84M	-$0.71	N/A

Canopy Growth has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market. Comparatively, Cumberland Pharmaceuticals has a beta of 0.08, suggesting that its share price is 92% less volatile than the broader market.

3.3% of Canopy Growth shares are held by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. 0.4% of Canopy Growth shares are held by company insiders. Comparatively, 42.1% of Cumberland Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Canopy Growth	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cumberland Pharmaceuticals has a net margin of -34.40% compared to Canopy Growth's net margin of -65.33%. Canopy Growth's return on equity of -21.91% beat Cumberland Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Canopy Growth	-65.33%	-21.91%	-14.34%
Cumberland Pharmaceuticals	-34.40%	-28.81%	-9.25%

Summary

Canopy Growth beats Cumberland Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Cumberland Pharmaceuticals compare to Atea Pharmaceuticals?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

In the previous week, Cumberland Pharmaceuticals had 1 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 2 mentions for Cumberland Pharmaceuticals and 1 mentions for Atea Pharmaceuticals. Cumberland Pharmaceuticals' average media sentiment score of 0.55 beat Atea Pharmaceuticals' score of 0.00 indicating that Cumberland Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cumberland Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atea Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cumberland Pharmaceuticals has a beta of 0.08, indicating that its share price is 92% less volatile than the broader market. Comparatively, Atea Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market.

Cumberland Pharmaceuticals has higher revenue and earnings than Atea Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$44.52M	2.57	-$2.84M	-$0.71	N/A
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.08	N/A

Atea Pharmaceuticals has a net margin of 0.00% compared to Cumberland Pharmaceuticals' net margin of -34.40%. Cumberland Pharmaceuticals' return on equity of -28.81% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-34.40%	-28.81%	-9.25%
Atea Pharmaceuticals	N/A	-64.25%	-57.12%

Atea Pharmaceuticals has a consensus target price of $7.00, suggesting a potential upside of 28.91%. Given Atea Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Atea Pharmaceuticals is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Atea Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are held by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are held by company insiders. Comparatively, 21.6% of Atea Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Cumberland Pharmaceuticals beats Atea Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Cumberland Pharmaceuticals compare to Adherex Technologies?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Adherex Technologies (NASDAQ:FENC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

Cumberland Pharmaceuticals has higher earnings, but lower revenue than Adherex Technologies. Adherex Technologies is trading at a lower price-to-earnings ratio than Cumberland Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$44.52M	2.57	-$2.84M	-$0.71	N/A
Adherex Technologies	$44.64M	8.87	-$9.74M	-$0.13	N/A

Cumberland Pharmaceuticals has a beta of 0.08, suggesting that its share price is 92% less volatile than the broader market. Comparatively, Adherex Technologies has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market.

Adherex Technologies has a consensus price target of $17.00, indicating a potential upside of 50.58%. Given Adherex Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Adherex Technologies is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Cumberland Pharmaceuticals had 2 more articles in the media than Adherex Technologies. MarketBeat recorded 2 mentions for Cumberland Pharmaceuticals and 0 mentions for Adherex Technologies. Cumberland Pharmaceuticals' average media sentiment score of 0.55 beat Adherex Technologies' score of 0.00 indicating that Cumberland Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Cumberland Pharmaceuticals	Positive
Adherex Technologies	Neutral

15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are owned by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are owned by insiders. Comparatively, 10.7% of Adherex Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Adherex Technologies has a net margin of -6.09% compared to Cumberland Pharmaceuticals' net margin of -34.40%. Adherex Technologies' return on equity of -5.71% beat Cumberland Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-34.40%	-28.81%	-9.25%
Adherex Technologies	-6.09%	-5.71%	-2.37%

Summary

Adherex Technologies beats Cumberland Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Cumberland Pharmaceuticals compare to Enanta Pharmaceuticals?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

In the previous week, Enanta Pharmaceuticals had 2 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 4 mentions for Enanta Pharmaceuticals and 2 mentions for Cumberland Pharmaceuticals. Cumberland Pharmaceuticals' average media sentiment score of 0.55 beat Enanta Pharmaceuticals' score of 0.21 indicating that Cumberland Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cumberland Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enanta Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cumberland Pharmaceuticals has higher earnings, but lower revenue than Enanta Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$44.52M	2.57	-$2.84M	-$0.71	N/A
Enanta Pharmaceuticals	$65.26M	6.01	-$81.89M	-$2.41	N/A

15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are owned by company insiders. Comparatively, 11.5% of Enanta Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Enanta Pharmaceuticals has a consensus target price of $19.50, indicating a potential upside of 44.77%. Given Enanta Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Enanta Pharmaceuticals is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Cumberland Pharmaceuticals has a beta of 0.08, suggesting that its share price is 92% less volatile than the broader market. Comparatively, Enanta Pharmaceuticals has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market.

Cumberland Pharmaceuticals has a net margin of -34.40% compared to Enanta Pharmaceuticals' net margin of -96.89%. Cumberland Pharmaceuticals' return on equity of -28.81% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-34.40%	-28.81%	-9.25%
Enanta Pharmaceuticals	-96.89%	-61.84%	-20.70%

Summary

Enanta Pharmaceuticals beats Cumberland Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Cumberland Pharmaceuticals compare to Palisade Bio?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Palisade Bio (NASDAQ:PALI) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

In the previous week, Palisade Bio had 9 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 11 mentions for Palisade Bio and 2 mentions for Cumberland Pharmaceuticals. Cumberland Pharmaceuticals' average media sentiment score of 0.55 beat Palisade Bio's score of -0.21 indicating that Cumberland Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cumberland Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Palisade Bio	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. Comparatively, 11.8% of Palisade Bio shares are held by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are held by insiders. Comparatively, 0.1% of Palisade Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Palisade Bio has a consensus price target of $9.00, indicating a potential upside of 328.57%. Given Palisade Bio's stronger consensus rating and higher probable upside, analysts clearly believe Palisade Bio is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

Cumberland Pharmaceuticals has higher revenue and earnings than Palisade Bio. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$44.52M	2.57	-$2.84M	-$0.71	N/A
Palisade Bio	$250K	1,463.87	-$16.78M	-$0.48	N/A

Cumberland Pharmaceuticals has a beta of 0.08, meaning that its stock price is 92% less volatile than the broader market. Comparatively, Palisade Bio has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market.

Palisade Bio has a net margin of 0.00% compared to Cumberland Pharmaceuticals' net margin of -34.40%. Cumberland Pharmaceuticals' return on equity of -28.81% beat Palisade Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-34.40%	-28.81%	-9.25%
Palisade Bio	N/A	-33.47%	-31.79%

Summary

Palisade Bio beats Cumberland Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

Get Cumberland Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CPIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CPIX vs. The Competition

Export

Metric	Cumberland Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$114.62M	$12.54B	$7.37B	$12.85B
Dividend Yield	N/A	2.61%	2.54%	11.08%
P/E Ratio	-10.77	789.80	272.88	24.24
Price / Sales	2.57	764.50	618.96	99.76
Price / Cash	20.86	96.77	78.62	53.99
Price / Book	6.71	11.89	13.05	6.20
Net Income	-$2.84M	$2.81B	$3.47B	$348.59M
7 Day Performance	-1.80%	1.77%	2.09%	0.08%
1 Month Performance	9.44%	3.85%	6.64%	3.88%
1 Year Performance	132.52%	6.56%	25.02%	16.98%

Cumberland Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CPIX Cumberland Pharmaceuticals	0.4811 of 5 stars	$7.65 +2.0%	N/A	+132.5%	$114.62M	$44.52M	N/A	80	News Coverage
CGC Canopy Growth	0.901 of 5 stars	$1.02 +2.6%	N/A	-17.3%	$455.15M	$251.01M	N/A	1,128
AVIR Atea Pharmaceuticals	1.762 of 5 stars	$5.45 +3.2%	$7.00 +28.4%	+48.4%	$437.06M	N/A	N/A	70	Gap Up
FENC Adherex Technologies	3.246 of 5 stars	$11.85 -0.2%	$17.00 +43.5%	+30.4%	$415.29M	$44.64M	N/A	10
ENTA Enanta Pharmaceuticals	1.6368 of 5 stars	$13.33 +0.2%	$19.50 +46.3%	+52.5%	$388.17M	$65.32M	N/A	160	News Coverage Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CPIX) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cumberland Pharmaceuticals (CPIX) Competitors

CPIX vs. CGC, AVIR, FENC, ENTA, and PALI

How does Cumberland Pharmaceuticals compare to Canopy Growth?

Summary

How does Cumberland Pharmaceuticals compare to Atea Pharmaceuticals?

Summary

How does Cumberland Pharmaceuticals compare to Adherex Technologies?

Summary

How does Cumberland Pharmaceuticals compare to Enanta Pharmaceuticals?

Summary

How does Cumberland Pharmaceuticals compare to Palisade Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPIX vs. The Competition

Cumberland Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cumberland Pharmaceuticals (CPIX) Competitors

CPIX vs. CGC, AVIR, FENC, ENTA, and PALI

How does Cumberland Pharmaceuticals compare to Canopy Growth?

Does the media refer more to CGC or CPIX?

Which has better valuation and earnings, CGC or CPIX?

Which has more risk & volatility, CGC or CPIX?

Do institutionals & insiders hold more shares of CGC or CPIX?

Do analysts recommend CGC or CPIX?

Is CGC or CPIX more profitable?

Summary

How does Cumberland Pharmaceuticals compare to Atea Pharmaceuticals?

Does the media prefer CPIX or AVIR?

Which has more risk & volatility, CPIX or AVIR?

Which has preferable valuation & earnings, CPIX or AVIR?

Is CPIX or AVIR more profitable?

Do analysts prefer CPIX or AVIR?

Do institutionals and insiders have more ownership in CPIX or AVIR?

Summary

How does Cumberland Pharmaceuticals compare to Adherex Technologies?

Which has higher earnings and valuation, CPIX or FENC?

Which has more volatility and risk, CPIX or FENC?

Do analysts rate CPIX or FENC?

Does the media favor CPIX or FENC?

Do institutionals and insiders hold more shares of CPIX or FENC?

Is CPIX or FENC more profitable?

Summary

How does Cumberland Pharmaceuticals compare to Enanta Pharmaceuticals?

Does the media favor CPIX or ENTA?

Which has preferable valuation and earnings, CPIX or ENTA?

Do insiders and institutionals believe in CPIX or ENTA?

Do analysts rate CPIX or ENTA?

Which has more risk & volatility, CPIX or ENTA?

Is CPIX or ENTA more profitable?

Summary

How does Cumberland Pharmaceuticals compare to Palisade Bio?

Does the media favor CPIX or PALI?

Do insiders & institutionals hold more shares of CPIX or PALI?

Do analysts prefer CPIX or PALI?

Which has stronger earnings and valuation, CPIX or PALI?

Which has more risk & volatility, CPIX or PALI?

Is CPIX or PALI more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPIX vs. The Competition

Cumberland Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools